Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Plasmodium Vivax Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans

NCT00935623
View directory record Official record
Conditions
Plasmodium Vivax Malaria
Interventions
Malaria Challenge
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Nov 15, 2026, 8:27 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria

NCT00295581
View directory record Official record
Conditions
Plasmodium Falciparum, Plasmodium Vivax Malaria
Interventions
PpPfs25/ISA51 & ScPvs25/ISA51
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 15, 2026, 8:27 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution

NCT02751294
View directory record Official record
Conditions
Malaria, Vivax
Interventions
Tafenoquine Control, Tafenoquine dissolution profile X, Tafenoquine SIL
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Nov 15, 2026, 8:27 AM EST
Not yet recruiting Not applicable Interventional

Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection

NCT07859800
View directory record Official record
Conditions
Healthy Volunteer, Malaria
Interventions
18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan
Diagnostic Test
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 54 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2026 · Synced Nov 15, 2026, 8:27 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate

NCT02184637
View directory record Official record
Conditions
Malaria, Vivax
Interventions
Tafenoquine, Dihydroartemisinin + Piperaquine tetraphosphate, Artemether + Lumefantrine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Nov 15, 2026, 8:27 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Genetic Variability in CYP2D6 in U.S Active Duty Population

NCT02960568
View directory record Official record
Conditions
Pharmacologic Action
Interventions
Primaquine
Drug
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 60 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Nov 15, 2026, 8:27 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Adaptive Interventions for Optimizing Malaria Control: a Cluster-Randomized SMART Trial

NCT04182126
View directory record Official record
Conditions
LLIN, PBO LLIN, IRS, Larviciding
Interventions
Regular long-lasting insecticidal nets, LLIN plus Piperonyl butoxide-treated LLIN, Long-lasting microbial larvicide, Indoor residual spraying with micro-encapsulated pirimiphos-methyl or other insecticides
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
6 Months and older
Enrollment
122,872 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Nov 15, 2026, 8:27 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Blood-Stage Plasmodium Vivax Cell Bank

NCT05095272
View directory record Official record
Conditions
Malaria
Interventions
HMPBS02-Pv
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Nov 15, 2026, 8:27 AM EST
Completed Phase 1 Interventional

Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults

NCT05913973
View directory record Official record
Conditions
Malaria
Interventions
Pvs230D1-EPA/Matrix-M
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Nov 15, 2026, 8:27 AM EST
Not yet recruiting Phase 1Phase 2 Interventional

Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M in Healthy Malaria-Naive Adults Using a Plasmodium Vivax Controlled Human Malaria Infection and Transmission Model

NCT07930585
View directory record Official record
Conditions
Healthy Volunteers, Malaria, Plasmodium Vivax
Interventions
Plasmodium vivax Challenge Agent Derived from PvHMB-CCE001, Pvs230D1-EPA/Matrix-M
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 54 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2026 · Synced Nov 15, 2026, 8:27 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

NCT00928083
View directory record Official record
Conditions
Malaria Falciparum, Malaria Vivax, Healthy Volunteers
Interventions
OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion, OZ439 800mg aqueous dispersion, OZ439 100mg API capsules, OZ439 400mg API capsules, OZ439 1600mg aqueous dispersion, OZ439 800mg API capsules, OZ439 1200mg API capsules, Placebo, OZ439 200mg aqueous dispersion
Drug
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Nov 15, 2026, 8:27 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)

NCT02658435
View directory record Official record
Conditions
Malaria, Vivax
Interventions
Tafenoquine 150 mg, Matched placebo 150mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
486 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Glendale, California • Overland Park, Kansas • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Nov 15, 2026, 8:27 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Tafenoquine Thorough QTc Study in Healthy Subjects

NCT01928914
View directory record Official record
Conditions
Malaria, Vivax
Interventions
Tafenoquine 300mg, Tafenoquine 600mg, Tafenoquine 1200mg, moxifloxacin, Placebo for Tafenoquine, Placebo for moxifloxaxin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Culver City, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Nov 15, 2026, 8:27 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults

NCT01157897
View directory record Official record
Conditions
Malaria, Plasmodium Vivax
Interventions
VMP001, P. vivax sporozoite challenge
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Nov 15, 2026, 8:27 AM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays

NCT06607003
View directory record Official record
Conditions
Malaria
Interventions
P. vivax challenge agent derived from PvHMB-CCE001
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 54 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 8:27 AM EST